NS Pharma, Inc.

Jul 01, 2025

NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases

May 14, 2025

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

Mar 10, 2025

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Nov 26, 2024

NS Pharma Announces Change in Commercial Leadership

Jul 10, 2024

NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization

May 27, 2024

NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study)

Mar 06, 2024

NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Clinical & Scientific Conference 2024